CHO is transiently expressed and can be used in therapeutic monoclonal antibodies
Among different bioprocessing technologies for manufacturing functional recombinant therapeutic proteins (e.g., monoclonal antibody drugs, hormones, and vaccines), yeast-based platforms are among the fastest, most flexible, and economically available to researchers from academia to pharma. Aside from Escherichia coli platforms, which provide several advantages over yeast, including a well-known system, easy workflow, and perhaps the most …
CHO is transiently expressed and can be used in therapeutic monoclonal antibodies Read More »